Cargando…

Effect of neoadjuvant chemotherapy (NAC) on programmed cell death ligand (PD-L1) in patients of carcinoma breast: A prospective study in Indian tertiary care setting

CONTEXT: Several studies have reported that PD-L1 has shown therapeutic activity in various tumor types. However, its expression changes in a person on administration of NAC which is reported by very few studies. AIMS: To find out the difference in the expression of PD-L1 by tumor cells after the ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Srivastava, Vipul, Akshay, BR, Kumari, Sweety, Meena, Ram Niwas, Khanna, Rahul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586517/
https://www.ncbi.nlm.nih.gov/pubmed/33110814
http://dx.doi.org/10.4103/jfmpc.jfmpc_493_20
_version_ 1783600011963006976
author Srivastava, Vipul
Akshay, BR
Kumari, Sweety
Meena, Ram Niwas
Khanna, Rahul
author_facet Srivastava, Vipul
Akshay, BR
Kumari, Sweety
Meena, Ram Niwas
Khanna, Rahul
author_sort Srivastava, Vipul
collection PubMed
description CONTEXT: Several studies have reported that PD-L1 has shown therapeutic activity in various tumor types. However, its expression changes in a person on administration of NAC which is reported by very few studies. AIMS: To find out the difference in the expression of PD-L1 by tumor cells after the administration of NAC. SETTINGS AND DESIGN: This prospective study was conducted on 30 patients who were diagnosed with locally advanced breast carcinoma (LABC) between 2017 and 2019 and those who received NAC followed by surgery. METHODS AND MATERIAL: Breast cancer specimens were collected using core needle biopsy prior to administration of NAC and IHC was performed. Frequency and staining intensity of PD-L1 by tumor cells were analyzed. PD-L1 expression was dichotomized into two groups according to the frequency distributions of the H-scores. STATISTICAL ANALYSIS USED: The differences in expression of PD-L1 along with various parameters were analyzed using Chi-square test and Student's t test. RESULTS: The mean age of the patients in our study was 51.37 ± 11.37 years. The response of NAC according to the RECIST criteria showed that most of patients (83.3%) showed complete response. Of the 30 cases, 11 (36.7%) patients were PD-L1 positive before the administration of NAC. We found a significant change in expression from positive to negative status, i.e., seven patients changed from positive to negative (p = 0.036). Upon comparing the PD-L1 expression before NAC, significant association was observed between the primary tumor (T) and tumor stage with high PD-L1 expression (p = 0.020 and P = 0.034). After NAC, 18 (69.2%) patients who were ER positive and 18 (69.2%) patients who were PR positive showed negative PD-L1 expression while none of them were positive in PD-L1 positive patients (p = 0.018 and P = 0.018). CONCLUSION: PD-L1 expression in a same person changes upon administration of NAC which may indirectly be used as a predictor of response to NAC.
format Online
Article
Text
id pubmed-7586517
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-75865172020-10-26 Effect of neoadjuvant chemotherapy (NAC) on programmed cell death ligand (PD-L1) in patients of carcinoma breast: A prospective study in Indian tertiary care setting Srivastava, Vipul Akshay, BR Kumari, Sweety Meena, Ram Niwas Khanna, Rahul J Family Med Prim Care Original Article CONTEXT: Several studies have reported that PD-L1 has shown therapeutic activity in various tumor types. However, its expression changes in a person on administration of NAC which is reported by very few studies. AIMS: To find out the difference in the expression of PD-L1 by tumor cells after the administration of NAC. SETTINGS AND DESIGN: This prospective study was conducted on 30 patients who were diagnosed with locally advanced breast carcinoma (LABC) between 2017 and 2019 and those who received NAC followed by surgery. METHODS AND MATERIAL: Breast cancer specimens were collected using core needle biopsy prior to administration of NAC and IHC was performed. Frequency and staining intensity of PD-L1 by tumor cells were analyzed. PD-L1 expression was dichotomized into two groups according to the frequency distributions of the H-scores. STATISTICAL ANALYSIS USED: The differences in expression of PD-L1 along with various parameters were analyzed using Chi-square test and Student's t test. RESULTS: The mean age of the patients in our study was 51.37 ± 11.37 years. The response of NAC according to the RECIST criteria showed that most of patients (83.3%) showed complete response. Of the 30 cases, 11 (36.7%) patients were PD-L1 positive before the administration of NAC. We found a significant change in expression from positive to negative status, i.e., seven patients changed from positive to negative (p = 0.036). Upon comparing the PD-L1 expression before NAC, significant association was observed between the primary tumor (T) and tumor stage with high PD-L1 expression (p = 0.020 and P = 0.034). After NAC, 18 (69.2%) patients who were ER positive and 18 (69.2%) patients who were PR positive showed negative PD-L1 expression while none of them were positive in PD-L1 positive patients (p = 0.018 and P = 0.018). CONCLUSION: PD-L1 expression in a same person changes upon administration of NAC which may indirectly be used as a predictor of response to NAC. Wolters Kluwer - Medknow 2020-08-25 /pmc/articles/PMC7586517/ /pubmed/33110814 http://dx.doi.org/10.4103/jfmpc.jfmpc_493_20 Text en Copyright: © 2020 Journal of Family Medicine and Primary Care http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Srivastava, Vipul
Akshay, BR
Kumari, Sweety
Meena, Ram Niwas
Khanna, Rahul
Effect of neoadjuvant chemotherapy (NAC) on programmed cell death ligand (PD-L1) in patients of carcinoma breast: A prospective study in Indian tertiary care setting
title Effect of neoadjuvant chemotherapy (NAC) on programmed cell death ligand (PD-L1) in patients of carcinoma breast: A prospective study in Indian tertiary care setting
title_full Effect of neoadjuvant chemotherapy (NAC) on programmed cell death ligand (PD-L1) in patients of carcinoma breast: A prospective study in Indian tertiary care setting
title_fullStr Effect of neoadjuvant chemotherapy (NAC) on programmed cell death ligand (PD-L1) in patients of carcinoma breast: A prospective study in Indian tertiary care setting
title_full_unstemmed Effect of neoadjuvant chemotherapy (NAC) on programmed cell death ligand (PD-L1) in patients of carcinoma breast: A prospective study in Indian tertiary care setting
title_short Effect of neoadjuvant chemotherapy (NAC) on programmed cell death ligand (PD-L1) in patients of carcinoma breast: A prospective study in Indian tertiary care setting
title_sort effect of neoadjuvant chemotherapy (nac) on programmed cell death ligand (pd-l1) in patients of carcinoma breast: a prospective study in indian tertiary care setting
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586517/
https://www.ncbi.nlm.nih.gov/pubmed/33110814
http://dx.doi.org/10.4103/jfmpc.jfmpc_493_20
work_keys_str_mv AT srivastavavipul effectofneoadjuvantchemotherapynaconprogrammedcelldeathligandpdl1inpatientsofcarcinomabreastaprospectivestudyinindiantertiarycaresetting
AT akshaybr effectofneoadjuvantchemotherapynaconprogrammedcelldeathligandpdl1inpatientsofcarcinomabreastaprospectivestudyinindiantertiarycaresetting
AT kumarisweety effectofneoadjuvantchemotherapynaconprogrammedcelldeathligandpdl1inpatientsofcarcinomabreastaprospectivestudyinindiantertiarycaresetting
AT meenaramniwas effectofneoadjuvantchemotherapynaconprogrammedcelldeathligandpdl1inpatientsofcarcinomabreastaprospectivestudyinindiantertiarycaresetting
AT khannarahul effectofneoadjuvantchemotherapynaconprogrammedcelldeathligandpdl1inpatientsofcarcinomabreastaprospectivestudyinindiantertiarycaresetting